Rachael Brake on Unmet Needs with EGFR Exon 20 Insertion-Mutant NSCLC #AACR2020 @rachael_brake @TakedaOncology

Rachael Brake on Unmet Needs with EGFR Exon 20 Insertion-Mutant NSCLC #AACR2020 @rachael_brake @TakedaOncology

User Photo
Cancer-News

4 months
53 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Rachael Brake @rachael_brake of Takeda @TakedaOncology discusses the therapy designation for mobocertinib (TAK-788) for the treatment of NSCLC patients with EGFR exon 20 insertion mutations
Up Next Autoplay